Can you use tranexamic acid with alpha arbutin?
The chemistry
Alpha arbutin is a glycoside of hydroquinone that competitively inhibits tyrosinase, the enzyme that builds melanin, without the irritation profile of hydroquinone itself (Boo 2021). Tranexamic acid does not touch tyrosinase directly. It blocks the plasminogen pathway that tells melanocytes to make more pigment and reduces the dilated vessels seen in melasma (Calacattawi 2024). Because one reduces the signal and the other reduces the enzyme, the pairing is logical. Both are water soluble and stable at skin-friendly pH. No reaction between them is known. Formulators like the pair because neither ingredient needs a very low pH, so a single serum can hold both at useful strengths without the stinging that acid-based brighteners cause. That makes it one of the few pigment combinations people with reactive or rosacea-prone skin can usually tolerate twice a day. Results are slow, and studies of each ingredient run for two to three months before measuring change.
Targets
Signal (tranexamic) versus enzyme (arbutin).
Irritation
Low for both; good for sensitive skin.
Format
Often in one serum; otherwise layer thinnest first.
Common mistakes
People sometimes combine this pair with high-strength acids and retinoids all at once, then blame the brighteners for redness. Another mistake is spot-applying on single marks; melasma is patchy and benefits from even coverage. Arbutin can convert to small amounts of hydroquinone in very high concentrations, so stick with products at 2 percent or less. It also helps to photograph marks in the same light every two weeks. Gradual fading is hard to see in a mirror, and people often quit a working routine because they cannot notice progress day to day.
Your routine
Morning
- Cleanser
- Tranexamic and arbutin serum
- Moisturizer
- Broad-spectrum SPF 50
Evening
- Cleanser
- Brightening serum
- Barrier cream
Go slower if
If you are pregnant, ask your doctor before using tranexamic acid or arbutin since data are limited. Pigment returns without sun protection, so treat sunscreen as part of the treatment. If a combined serum also contains niacinamide or kojic acid, patch test, since kojic acid is a known contact allergen.
Evidence strength
Moderate for topical tranexamic acid (Yasnova 2024, Calacattawi 2024), limited to moderate for arbutin (Boo 2021). No trial isolates this pair.
Products with alpha arbutin
The Ordinary Alpha Arbutin 2% + HA
Picked for alpha arbutin
2% alpha arbutin with hydrolyzed hyaluronic acid and ergothioneine.
Buy on Amazon (opens in a new tab)FAQ
Is this pair better than hydroquinone?
Hydroquinone is stronger, but this pair is gentler for long-term use.
How long until results?
Expect 8 to 12 weeks for visible change.
Can I add vitamin C?
Yes. Use it in the morning, and add it two weeks after the serum so you can judge how your skin handles each.
Does it help freckles?
Somewhat. Freckles darken with sun, so sunscreen matters more.
Can I use this with retinol?
Yes. Put the brightening serum on first at night and retinol after, or keep the serum for mornings only.
Can I use both twice daily?
Yes, both are usually gentle enough for morning and night.
Related combinations
- RetinolYes
- Vitamin CYes
- NiacinamideYes
- RetinolYes
- TretinoinYes
- Vitamin CYes
- NiacinamideYes
- Salicylic AcidYes
Sources
- Boo YC. Arbutin as a skin depigmenting agent with antimelanogenic and antioxidant properties. Antioxidants (Basel). 2021;10(7):1129.
- Calacattawi R, et al. Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials. J Dermatolog Treat. 2024;35(1):2361106.
- Yasnova N, Sirait SP, Rahmayunita G. The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial. Acta Dermatovenerol Alp Pannonica Adriat. 2024;33(2):83-88.
- Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: a systematic review of randomized controlled trials. J Drugs Dermatol. 2019;18(11):S1545961619P1156X.